Halozyme Therapeutics Ownership
| HALO Stock | USD 51.44 5.79 12.68% |
Shares in Circulation | First Issued 2002-03-31 | Previous Quarter 131 M | Current Value 128.9 M | Avarage Shares Outstanding 100.2 M | Quarterly Volatility 43.5 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Halozyme |
Halozyme Stock Ownership Analysis
About 99.0% of the company shares are owned by institutional investors. The company had not issued any dividends in recent years. Halozyme Therapeutics had 171:40 split on the 10th of December 2003. Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California. Halozyme Therapeutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 145 people. To learn more about Halozyme Therapeutics call Todd Butler at 858 794 8889 or check out https://halozyme.com.Besides selling stocks to institutional investors, Halozyme Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Halozyme Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Halozyme Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Halozyme Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Halozyme Therapeutics Insider Trades History
Only 1.11% of Halozyme Therapeutics are currently held by insiders. Unlike Halozyme Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Halozyme Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Halozyme Therapeutics' insider trades
Halozyme Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Halozyme Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Halozyme Therapeutics backward and forwards among themselves. Halozyme Therapeutics' institutional investor refers to the entity that pools money to purchase Halozyme Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Gw&k Investment Management, Llc | 2024-03-31 | 2.2 M | Amvescap Plc. | 2023-12-31 | 2 M | Northern Trust Corp | 2023-12-31 | 2 M | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-03-31 | 1.9 M | Thrivent Financial For Lutherans | 2024-03-31 | 1.7 M | Dimensional Fund Advisors, Inc. | 2024-03-31 | 1.7 M | Charles Schwab Investment Management Inc | 2024-03-31 | 1.7 M | Stephens Inv Mgmt Group Llc | 2024-03-31 | 1.5 M | Nuveen Asset Management, Llc | 2023-12-31 | 1.5 M | Blackrock Inc | 2023-12-31 | 18.6 M | Vanguard Group Inc | 2024-03-31 | 13 M |
Halozyme Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Halozyme Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Halozyme Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Halozyme Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Halozyme Therapeutics' latest congressional trading
Congressional trading in companies like Halozyme Therapeutics, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Halozyme Therapeutics by those in governmental positions are based on the same information available to the general public.
| 2017-12-08 | Senator Mark Warner | Acquired $500,001 - $1,000,000 | Verify |
Halozyme Therapeutics Corporate Filings
F4 | 22nd of May 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 7th of May 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 25th of April 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
| 15th of March 2024 Other Reports | ViewVerify |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Information and Resources on Investing in Halozyme Stock
When determining whether Halozyme Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Halozyme Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Halozyme Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Halozyme Therapeutics Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Halozyme Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Halozyme Therapeutics. If investors know Halozyme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Halozyme Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.069 | Earnings Share 2.41 | Revenue Per Share 6.643 | Quarterly Revenue Growth 0.208 | Return On Assets 0.1348 |
The market value of Halozyme Therapeutics is measured differently than its book value, which is the value of Halozyme that is recorded on the company's balance sheet. Investors also form their own opinion of Halozyme Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Halozyme Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Halozyme Therapeutics' market value can be influenced by many factors that don't directly affect Halozyme Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Halozyme Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Halozyme Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Halozyme Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.